John M Burke, MD from Rocky Mountain Cancer Centers discusses lymphoid malignancies treatment developments and replacement of Bleomycin with Brentuximab Vedotin at the 2017 American Society of Hematology.
John M Burke, MD from Rocky Mountain Cancer Centers discusses lymphoid malignancies treatment developments and replacement of Bleomycin with Brentuximab Vedotin at the 2017 American Society of Hematology.